Uncategorized

DOWNLOAD Chair of Translational Neuro-Oncology at the University of Manchester, previously a member of the Company’s Scientific Advisory Board, elected at the 2026 Annual General Meeting VANCOUVER, British Columbia, September 10, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced […]

DOWNLOAD Financing completed at the full upsized amount following strong investor demand VANCOUVER, British Columbia, August 31, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce that it has closed the second and final tranche (the “Second Tranche”)

VANCOUVER, British Columbia, August 19, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce the results of voting at its 2026 annual general meeting of shareholders held on August 18, 2026, in Toronto, Ontario (the “Meeting”). All five

Expanded financing broadens Rakovina’s strategic investor base and reinforces confidence in its AI-powered oncology platform DOWNLOAD VANCOUVER, British Columbia, August 12, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce that it has closed the first tranche (the

DOWNLOAD VANCOUVER, British Columbia, July 15, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV)( FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, today announces a non-brokered private placement offering (the “Offering”) of up to $1.5 million. Pursuant to the Offering, Rakovina will issue up to 15 million

All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, June 1, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced its financial results for the three months ended March 31, 2026 (“Q1 2026”), and provided an

download VANCOUVER, British Columbia, April 30, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2025, and provided a corporate update. As Rakovina enters 2026, the Company

AI-Designed Dual ATR-mTOR Inhibitor Demonstrates In Vivo Efficacy; Novel LNP Formulation of Bifunctional PARP/HDAC Inhibitor kt-3283 Successfully Characterized VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced the presentation of new preclinical data from two

Accepted Abstracts Highlight Advances in AI-Driven Oncology Pipeline VANCOUVER, British Columbia, March 23, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce that two research abstracts have been accepted for presentation at the upcoming 2026 American Association for

VANCOUVER, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce that the TSXV has granted the Company a 30-day extension with respect to its non-brokered private placement financing (the “Offering”), previously announced on January